Details for New Drug Application (NDA): 020695
✉ Email this page to a colleague
The generic ingredient in RAXAR is grepafloxacin hydrochloride. Additional details are available on the grepafloxacin hydrochloride profile page.
Summary for 020695
Tradename: | RAXAR |
Applicant: | Otsuka |
Ingredient: | grepafloxacin hydrochloride |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 200MG BASE | ||||
Approval Date: | Nov 6, 1997 | TE: | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 400MG BASE | ||||
Approval Date: | May 14, 1998 | TE: | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 600MG BASE | ||||
Approval Date: | May 14, 1998 | TE: | RLD: | No |
Expired US Patents for NDA 020695
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Otsuka | RAXAR | grepafloxacin hydrochloride | TABLET;ORAL | 020695-001 | Nov 6, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription